Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Gray-Zone Lymphoma”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Testing effectiveness (Phase 2)UnknownNCT04860674
What this trial is testing

A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma

Who this might be right for
Gray Zone LymphomaRelapse/RecurrenceChemotherapy Effect
Zhejiang Cancer Hospital 20
Early research (Phase 1)Active Not RecruitingNCT03602157
What this trial is testing

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Who this might be right for
LymphomaImmune System DiseasesImmunoproliferative Disorders+10 more
UNC Lineberger Comprehensive Cancer Center 43
Testing effectiveness (Phase 2)Looking for participantsNCT07283822
What this trial is testing

Amping up With PemJAK

Who this might be right for
Non-Hodgkin LymphomaHodgkin Disease LymphomaNon-Hodgkin Lymphoma Refractory/ Relapsed+5 more
Seda S. Tolu 53
Testing effectiveness (Phase 2)Study completedNCT03255018
What this trial is testing

Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

Who this might be right for
Non-Hodgkin LymphomaLymphomaDiffuse Large B-Cell Lymphoma+2 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Study completedNCT03610724
What this trial is testing

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Who this might be right for
Non-Hodgkin Lymphoma
Novartis Pharmaceuticals 34
Early research (Phase 1)Study completedNCT02568553
What this trial is testing

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Burkitt LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+23 more
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54
Very early researchUnknownNCT05208853
What this trial is testing

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Who this might be right for
Hodgkin LymphomaNK/T Cell LymphomaPeripheral T Cell Lymphoma, Unspecified+5 more
Zhejiang University 9
Early research (Phase 1)Study completedNCT01943682
What this trial is testing

Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaBurkitt Lymphoma+5 more
Children's Hospital Medical Center, Cincinnati 27
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Testing effectiveness (Phase 2)Active Not RecruitingNCT05507541
What this trial is testing

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent ALK Positive Large B-Cell LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+25 more
Mayo Clinic 10